The first new treatment for Alzheimer’s disease in nearly 20 years has been approved by regulatory authorities in the United States. Aducanumab targets the underlying cause of Alzheimer’s, the most common form of dementia, rather than its symptoms. However, scientists are divided over its potential impact due to uncertainty surrounding the trial results. The U.S. Food and Drug Administration (FDA) stated that there is “substantial evidence that aducanumab reduces beta-amyloid plaques in the brain” and that this “is reasonably likely to provide important benefits for patients.”
